In addition, the YAP-induced HCC mice model showed significant tumor occurrence inhibition, suppressing the tumor markers of AFP and DCP when DTA was administered within the first 4 months after the initiation of oncogene (Figure 3 and Figure 4). The gene discussed is ACE; the disease is neoplasm.